RenovoRx Inc (RNXT) Actualités

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Initial Revenues Expected this Quarter, and Customer Pipeline for RenovoCath Standalone Device Continues to Expand, Including High Volume...

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Pre-Clinical Data Recently Presented at the SIO 2025 Annual Conference Show that Intra-Arterial Administration of a Drug with the RenovoCath®...

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Financing led by new fundamental healthcare institutional investors RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and...

Form 424B5 - Prospectus [Rule 424(b)(5)]

RenovoRx Announces Proposed Public Offering

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and...

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Abstract was presented by TIGeR-PaC Phase III clinical trial Investigator, Paula Novelli, MD, from the University of Pittsburgh Medical Center...

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium

Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium PR...

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Two additional abstracts have been accepted to be presented at upcoming prestigious industry conferences, SIO 2025 and SSO 2025 The accepted...

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

RenovoRx Holds a Strong IP Portfolio with 18 Issued Patents and 13 Pending Patents as it Moves Forward with Commercialization and Clinical Trial...

RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of...

RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

LOS ALTOS, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq:...